摘要
二甲双胍作为T2DM患者的一线用药已被广泛共识,但T2DM是一种进行性疾病,起始采用二甲双胍单药治疗的患者,随时间的推移和病程的进展,常需联合其他口服降糖药物,如磺脲类、格列奈类、TZDs、α-葡萄糖苷酶抑制剂(AGDI)、二肽基肽酶-4(DPP-4)抑制剂、胰升血糖素样肽-1(GLP-1)受体激动剂或胰岛素制剂来控制血糖。本文就二甲双胍与其他降糖药物联用的临床疗效研究进展作一综述。
Metformin was widely recommended as a first-line drug for patients with type 2 diabetes mellitus（T2DM）.However,studies have shown that patients who start metformin as monotherapy often required additional agents to maintain glycaemic control with the natural progression of T2DM.Antidiabetic agents may be used in combination with metformin,including sulfonylureas,glinides,thiazolidinediones（TZDs）,α-glucosidase inhibitor（AGDI）,dipeptidyl peptidase-4inhibitor（DPP-4）and glucagon-like peptide-1（GLP-1）or insulin.This paper mainly reviews the recent studies about the therapeutic effect of metformin in combination with other anti-diabetic agents.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2015年第2期178-181,共4页
Chinese Journal of Diabetes
基金
国家自然科学基金面上项目(81070650、81270397)
关键词
二甲双胍
联合治疗
降糖药物
疗效
Metformin
Combination therapy
Hypoglycemic agent
Efficacy
